Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

Pathophysiology of Vomiting

Pathophysiology of Vomiting

Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through interaction...

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.

Thyroid : official journal of the American Thyroid Association·2010

Same author

Correlation between drugs of abuse and alcohol by hair analysis: parents at risk for having children with fetal alcohol spectrum disorder.

Alcohol (Fayetteville, N.Y.)·2010

Same author

Electrophysiological studies of transgenic long QT type 1 and type 2 rabbits reveal genotype-specific differences in ventricular refractoriness and His conduction.

American journal of physiology. Heart and circulatory physiology·2010

Same author

Comparison of the novel HK-2 human renal proximal tubular cell line with the standard LLC-PK1 cell line in studying drug-induced nephrotoxicity.

Canadian journal of physiology and pharmacology·2010

Same author

Severe extrapiramidal symptoms after nonintentional risperidone exposure in a child: case report and review of the literature.

American journal of therapeutics·2010

Same author

Pediatric cancer rates after universal folic acid flour fortification in Ontario.

Journal of clinical pharmacology·2010

Search research articles

Related Experiment Video

Updated: May 14, 2026

Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting

Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting

Published on: August 4, 2023

Treating morning sickness PRN?

¹for Duchesnay Inc., Blainville, Quebec, Canada.

Canadian Family Physician Medecin De Famille Canadien

|February 19, 2013

Summary

Treating morning sickness consistently is crucial for adequate intake. Intermittent treatment may not be effective for nausea and vomiting of pregnancy (NVP) symptoms that can last for months.

Area of Science:

Obstetrics and Gynecology
Maternal-Fetal Medicine

Background:

Morning sickness, or nausea and vomiting of pregnancy (NVP), is a common condition.
Current advice suggests intermittent treatment (pro re nata) for moderate NVP symptoms.

Purpose of the Study:

To evaluate the efficacy of intermittent treatment for morning sickness.
To determine the appropriate management strategy for nausea and vomiting of pregnancy.

Main Methods:

This is a clinical question based on a patient's reported experience.
The response is based on established medical knowledge regarding NVP management.

Main Results:

Intermittent treatment (pro re nata) is generally not recommended for moderate NVP.

More Related Videos

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

Related Experiment Videos

Last Updated: May 14, 2026

Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting

Ear Plaster Therapy as a Safe and Effective Treatment for Gestational Vomiting

Published on: August 4, 2023

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting

Published on: June 21, 2024

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

How to Study Placebo Responses in Motion Sickness with a Rotation Chair Paradigm in Healthy Participants

Published on: December 14, 2014

Consistent symptom management is critical for maintaining adequate fluid and calorie intake.

Conclusions:

Nausea and vomiting of pregnancy often requires consistent management, potentially lasting for weeks or months.
Gradual dose reduction of antiemetic medication is advised as symptoms improve.